Interfakultäres Institut für Genetik und Funktionelle Genomforschung, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald, Germany.
Proteomics. 2010 May;10(9):1802-18. doi: 10.1002/pmic.200900734.
Enteroviral myocarditis displays highly diverse clinical phenotypes ranging from mild dyspnoea or chest pain to cardiogenic shock and death. Despite detailed studies of the virus life cycle in vitro and in vivo, the molecular interplay between host and virus in disease progression is largely unresolved. Murine models of Coxsackievirus B3 (CVB3)-induced myocarditis well mimic the human disease patterns and can thus be explored to study mechanisms leading from acute to chronic myocarditis. Here, we present a 2-D gel-based proteomic survey of the changes in the murine cardiac proteome that occurs following infection with CVB3. In total, 136 distinct proteins were affected. Proteins, which are involved in immunity and defense and protein metabolism/modification displayed pronounced changes in intensity not only during acute but also at later stages of CVB3 myocarditis. Proteins involved in maintenance of cell structure and associated proteins were particularly influenced in the acute phase of myocarditis, whereas reduction of levels of metabolic enzymes was observed in chronic myocarditis. Studies about changes in protein intensities were complemented by an analysis of protein phosphorylation that revealed infection-associated changes in the phosphorylation of myosin binding protein C, atrial and ventricular isoforms of myosin regulatory light chain 2, desmin, and Rab GDP dissociation inhibitor beta-2.
肠道病毒心肌炎表现出高度多样化的临床表型,从轻度呼吸困难或胸痛到心源性休克和死亡不等。尽管对病毒在体外和体内的生命周期进行了详细的研究,但宿主和病毒在疾病进展中的分子相互作用在很大程度上仍未得到解决。柯萨奇病毒 B3(CVB3)诱导的心肌炎小鼠模型很好地模拟了人类疾病模式,因此可以用来研究从急性心肌炎向慢性心肌炎发展的机制。在这里,我们对感染 CVB3 后小鼠心脏蛋白质组的变化进行了基于 2-DE 凝胶的蛋白质组学调查。总共有 136 种不同的蛋白质受到影响。参与免疫和防御以及蛋白质代谢/修饰的蛋白质不仅在急性阶段,而且在 CVB3 心肌炎的后期阶段,其强度也发生了明显变化。参与维持细胞结构和相关蛋白质的蛋白质在心肌炎的急性期受到特别影响,而代谢酶水平的降低则发生在慢性心肌炎中。对蛋白质强度变化的研究通过对蛋白质磷酸化的分析得到了补充,该分析揭示了肌球蛋白结合蛋白 C、心房和心室肌球蛋白调节轻链 2 的磷酸化、结蛋白和 Rab GDP 解离抑制剂β-2 的感染相关变化。